Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
Bengaluru: Novo Nordisk's announced on Monday that an oral version of its drug semaglutide significantly lowered the risk of cardiovascular events in patients during a late-stage study.
The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack and stroke, by 14% compared to placebo, meeting the main goal of the trial.
The study tested the drug as an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease, the company said.
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
The drugmaker said detailed results from the study will be presented at a scientific conference next year.
Next Story